Juan Fortea

Cargo

Neurologist at the Memory Unit of the Neurology Service of the Hospital de la Santa Creu i Sant Pau in Barcelona and coordinator of the Study Group of Behavioural Neurology and Dementias of the Spanish Society of Neurology

Hospital de la Santa Creu i Sant Pau, Spanish Society of Neurology

Topics

Alzheimer's, neurology, neurodegenerative diseases

Reactions: data from Alzheimer's clinical trial with lecanemab antibody published

Alzheimer's

Reactions: data from Alzheimer's clinical trial with lecanemab antibody published

SMC Spain

A few weeks ago, a press release from the Biogen and Eisai companies reported significant results from their lecanemab antibody for the treatment of early-stage Alzheimer's. The data from the phase 3 trial are now published in the New England Journal of Medicine, coinciding with the CTAD conference on Alzheimer's disease clinical trials in San Francisco. Data from the phase 3 clinical trial are now published in the New England Journal of Medicine, coinciding with the 15th CTAD Alzheimer's disease clinical trials conference in San Francisco.

Potential fraud in major Alzheimer's research: what are the implications?

Alzheimer's

Potential fraud in major Alzheimer's research: what are the implications?

SMC Spain

Science magazine has published a report revealing multiple indications of fraud in one of the most cited publications on Alzheimer's disease. We explain what it means for the science that studies this disease.

Subscribe to RSS - Juan Fortea